Intravenous and Intraperitoneal Paclitaxel and Oral Nilotinib for Peritoneal Carcinomatosis From Ovarian, Colorectal, or Appendiceal Cancer
Tumors that have spread to the lining of the abdomen from other cancers, such as cancer of the appendix, colon, or ovary, are called peritoneal carcinomatosis. In most cases, outcomes are poor. Researchers want to test a new treatment.
To learn if the combination of oral nilotinib plus paclitaxel given by IV and directly into the abdomen can reduce tumors enough for people to have surgery.
Adults aged 18 and older with peritoneal carcinomatosis that is too widespread for surgery.
Participants will be screened with:
Blood and urine tests
Laparoscopy. They will get general anesthesia. Small cuts will be made in their abdomen. Tissue and fluid samples will be taken.
Surveys about their health
CT scans of their torso
Participants will have up to 4 more laparoscopies. During the first procedure, a port will be placed under the skin of their abdomen (an IP port). It will be attached to a catheter that is placed in their abdomen.
Participants will get treatment in 3-week cycles, for 3 or 6 cycles. They will take nilotinib by mouth twice daily. They will get paclitaxel by IP port (once per cycle) and by IV (twice per cycle). After cycles 3 and 6, they will have a laparoscopy and CT scans. Then they may take nilotinib and get IV paclitaxel for up to 1 year.
At study visits, participants will repeat some screening tests.
About 6 weeks after treatment ends and then every 3 months for 3 years, participants will have follow-up visits at NIH or with their local doctor.
|Condition or Disease||Intervention/Treatment||Phase|
Peritoneal carcinomatosis is uniformly fatal if untreated; despite advances in systemic chemotherapy, cytoreductive surgery, and intraperitoneal chemotherapy, survival remains poor for the majority of patients
The combination of oral nilotinib and intravenous paclitaxel has demonstrated pre-clinical and clinical synergism in the treatment of solid tumors, with an ongoing Phase I trial at the NIH
The synergy of oral nilotinib with intraperitoneal paclitaxel remains to be characterized
This study involves the combination of intravenous and intraperitoneal paclitaxel and oral nilotinib for unresectable peritoneal carcinomatosis from ovarian, colorectal, or appendiceal histologies
-To evaluate efficacy of bidirectional chemotherapy using intraperitoneal and intravenous paclitaxel and oral nilotinib by calculating the rate of downstaging of peritoneal disease burden to become resectable, based on Peritoneal Carcinomatosis Index (PCI)
Participants >= 18 years of age with histologically confirmed non-mucinous peritoneal carcinomatosis of ovarian, colorectal, or appendiceal histology
Demonstrated resistance or lack of response to at least one line of already approved and available systemic chemotherapy
No history of allergic reactions attributed to compounds of similar chemical or biologic composition to study drugs
No intraperitoneal chemotherapy within the last six months
Deemed unable to undergo complete cytoreduction
Phase II open-label, non-randomized study
After confirmation of eligibility, at the time of diagnostic laparoscopy, biopsies will be taken, and an intraperitoneal catheter will be placed for subsequent chemotherapy administration
Up to 6 cycles will be planned, with restaging laparoscopy and biopsies after Cycles 3 and 6
Arms and Interventions
|Experimental: 1/ IP Catheter Placement and Bidirectional Chemotherapy|
IP and IV paclitaxel administration with oral nilotinib
Paclitaxel: Intraperitoneal (IP) paclitaxel will be dosed at 60 mg/m2 to be infused over 1 hour on Day 1 of each 3-week cycle; participants with unresectable, but stable or responding disease after C1 through C3 will dose increase IP paclitaxel to 80 mg/m2 for Cycles 4-6. Intravenous (IV) paclitaxel will be infused over 1 hour on Day 2 of the first week of Cycle 1, followed by Day 1 of the subsequent treatment weeks; IV paclitaxel will be dosed at 60 mg/m2 for Week 1 of Cycle 1 and, if tolerated, at 80 mg/m2 for subsequent treatments.
Oral nilotinib will be dosed at 300 mg twice daily. Nilotinib will be administered continually from the loading dose (Day -4) leading up to laparoscopy #2 onward.
Primary Outcome Measures
- Evaluate efficacy of bidirectional chemotherapy using intraperitoneal and intravenous paclitaxel and oral nilotinib by calculating the rate of downstaging of peritoneal disease burden to become resectable, based on Peritoneal Carcinomatosis Inde... [baseline, every 9 weeks during treatment, and then every 3 months for 3 years]
Rate of downstaging- i.e., the fraction of participants who are successfully downstaged to resectable based on PCI and PI discretion. The fraction of participants who are successfully down-staged to resectable by use of chemotherapy will be reported along with a 95% confidence interval.
Secondary Outcome Measures
- Assess clinicopathologic response to therapy [baseline, every 9 weeks during treatment, and then every 3 months for 3 years]
Response rate by RECIST 1.1 and/or by PCI: the fractions with a clinical response will be reported for all participants along with a 95% confidence interval.
- Evaluate the peritoneal progression-free survival (pPFS) probability and the percentage of participants who become resectable by individual histologies [baseline, at peritoneal disease relapse from CR or peritoneal disease progression, for up to 3 years after completion of therapy]
Peritoneal progression-free survival (pPFS) probability and the percentage of participants who become resectable will be evaluated by individual histologies; median peritoneal progression-free survival (pPFS) will be reported using the Kaplan-Meier method, along with a 95% confidence interval for each histology. The fraction who are able to be down-staged to resectable will be reported for each histology along with a 95% confidence interval.
- Evaluate safety and tolerability of therapy [on-going throughout treatment]
Safety will be assessed by analyzing the type, grade and frequency of toxicities in addition to laboratory data and vital signs. Adverse events (AEs) will be assessed using CTCAE v.5.0
- Determine peritoneal progression-free survival (pPFS) [baseline, at peritoneal disease relapse from CR or peritoneal disease progression, for up to 3 years after completion of therapy]
Kaplan-Meier method will be used to evaluate peritoneal progression-free survival (pPFS); the median peritoneal progression-free survival (pPFS) will be reported along with a 95% two-sided confidence interval, to be done for all participants.
- Measure overall survival (OS) and overall progression-free survival (PFS) [baseline, at peritoneal disease relapse from CR or peritoneal disease progression, or death, for up to 3 years after completion of therapy]
Kaplan-Meier method will be used; a 95% confidence interval will be reported on the median overall survival (OS) and overall progression-free survival (PFS).
- Evaluate participants quality of life (QOL) [baseline, every 9 weeks while on treatment, then every 3 months for 3 years after completion of study therapy]
Outcomes from QOL will be reported using descriptive statistics, as well as comparing the results from before to after treatment: physical and mental health-related quality of life.
- INCLUSION CRITERIA:
In order to be eligible to participate in this study, an individual must meet all of the following criteria.
Histological confirmation of non-mucinous peritoneal carcinomatosis from ovarian, colorectal, or appendiceal primary by the Laboratory of Pathology, NCI.
Participants must have been treated with at least one line of approved systemic chemotherapy, with demonstrated resistance or lack of response
Measurable or evaluable disease as defined by RECIST v1.1. criteria and/or by Peritoneal Carcinomatosis Index (PCI)
Participants must be assessed to not be candidates for cytoreductive surgery, with PCI score > 30 on screening laparoscopy or with extensive small bowel serosal involvement
Age >= 18 years
ECOG performance status <= 2 (Karnofsky >= 60%).
Participants must have adequate organ and marrow function as defined below:
Leukocytes >= 3,000/mcL
Absolute neutrophil count >= 1,000/mcL
Platelets >= 100,000/mcL
Total bilirubin within <= 1.5x institutional upper limit of normal (ULN)
AST (SGOT)/ ALT (SGPT) <= 2.5x institutional ULN
Serum amylase and lipase <= 1.5x institutional ULN
Serum potassium and magnesium greater than institutional lower limit of normal
Creatinine <= 1.5 mg/dL or creatinine clearance >= 60 mL/min/1.73 m2 for participants with creatinine levels above institutional normal calculated using eGFR
Breastfeeding participant must agree to discontinue breastfeeding.
Females of child-bearing potential must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry, for the duration of study participation and for 90 days after last study treatment. Should a female suspect she is pregnant while she is participating in this study, she should inform her treating physician immediately.
Ability of participant to understand and the willingness to sign a written informed consent document.
Participants must agree to co-enrollment on the tissue collection protocol 13C0176, Tumor, Normal Tissue and Specimens from Patients Undergoing Evaluation or Surgical Resection of Solid Tumors
Participants must agree to co-enrollment on protocol 06-C-0213, Tissue Procurement Protocol
An individual who meets any of the following criteria will be excluded from participation in this study.
Participants who are receiving any other investigational agents or has received an investigational agent within 30 days prior to the start of study treatment.
History of allergic reactions attributed to compounds of similar chemical or biologic composition to study drugs.
Participants who have received intravenous chemotherapy within the last 4 weeks or who have undergone major surgery within the last 12 weeks prior to the start of study treatment.
Previous intraperitoneal chemotherapy within the last 6 months.
Participants requiring the use of drugs known to prolong the QT interval or known to strongly inhibit CYP3A4, 2C8. Participants on such agents at the time of screening are permitted on study if an alternative that does not have the same pharmacokinetic interactions can be found.
Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements. Note: No subject will be excluded based on a social situation prior to consultation with the Department of Social Work.
Pregnant women are excluded from this study.
Patients with HIV who have detectable viral load, or whose ART contains QTc Prolonging Medications or CYP3A4 Inhibitors regardless of viral load. (NOTE: Patients with HIV who have an undetectable viral load and have been on stable doses of ART that does not prolong the QT interval or is a strong CYP3A4, 2C8 inhibitor are eligible).
QTcF interval of >= 450 msec at study entry, or congenital long QT syndrome.
More than 3 liters of ascites present at initial laparoscopy, or history of more than two paracentesis procedures in the 30 days prior to initial laparoscopy.
Advanced hepatic failure, as indicated by Child-Pugh Class C cirrhosis.
Sensory/motor neuropathy >= Grade 2
Contacts and Locations
|1||National Institutes of Health Clinical Center||Bethesda||Maryland||United States||20892|
Sponsors and Collaborators
- National Cancer Institute (NCI)
- Principal Investigator: Andrew M Blakely, M.D., National Cancer Institute (NCI)
Study Documents (Full-Text)None provided.